This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

REGULATORY

Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable

The pharma industry is jittery about an increasingly likely NHI price revision in April 2017, but a senior health ministry official hints that market price-based price cuts could be dodged ... > Read full story
REGULATORY
Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme (Mar.03)
BUSINESS
Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan (Mar.03)
ACADEMIA
Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year (Mar.03)
BUSINESS
Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai (Mar.03)
ACADEMIA
No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ. (Mar.02)
> More Latest News

Photosmore

  
No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ. (Mar.02)Eli Lilly Aims to Lead Japan Diabetes Market by 2020 (Mar.02)MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi (Feb.27)
  
Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma (Feb.27)MHLW OKs 60 New APIs in 2014, Doubling from Year Ago (Feb.26)New Division for Cancer and Specific Diseases Control to Handle Hepatitis Measures after Reorganization of HSB (Feb.24)

News Categories

REGULATORY
   Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme(Mar.03)
   Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable(Mar.03)
   MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime(Mar.02)
BUSINESS
   Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan(Mar.03)
   Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai(Mar.03)
   Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence(Mar.02)
ORGANIZATION
   Medwatcher Accuses HPV Vaccine Makers of Violating JPMA’s Promotion Code(Mar.02)
   JPMA to Inform Medical Institutions of New R&D Cost Disclosure Plan in April(Feb.20)
   AJMC Announces Guidelines for Investigator-Led Clinical Trials(Feb.20)
ACADEMIA
   Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year(Mar.03)
   No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.(Mar.02)
   Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma(Feb.27)

Commentary

As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse

Lexicon

Conditional, Time-Limited Approval:
条件・期限付き承認

The Column

Sales Experience for Marketers Deceasing in Japan’s Pharma Industry

Archives

MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime(Mar.02)
Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence(Mar.02)
Medwatcher Accuses HPV Vaccine Makers of Violating JPMA’s Promotion Code(Mar.02)
PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia(Mar.02)
Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka(Mar.02)

Most Read

1.
Novartis Slappe...
2.
MHLW OKs 60 New...
3.
Shelved Decisio...
4.
Govt-Backed Res...
5.
Medicago Signs ...

News Calendar